Meeting
2023 ASCO Annual Meeting
Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI).
Authors
Michelle Christine Janelsins
University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY
Michelle Christine Janelsins , Umang Gada , Eva Culakova , Mohamedtaki Abdulaziz Tejani , Tim Ahles , Javier Bautista , Mark Allen O'Rourke , Jeffrey L. Berenberg , Nguyet Le-Lindqwister , Steven Eric McCormack , Husain Rasheed , Gary R. Morrow , Karen Michelle Mustian , Luke Joseph Peppone , Supriya Gupta Mohile , Richard Francis Dunne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT03186638
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12116)
DOI
10.1200/JCO.2023.41.16_suppl.12116
Abstract #
12116
Poster Bd #
484
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Phase 3 randomized controlled trial comparing the effectiveness of dexamethasone in reducing cancer-associated fatigue in patients on palliative chemotherapy.
First Author: Venkatraman Radhakrishnan
Poster
2014 ASCO Annual Meeting
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153.
First Author: Costantine Albany
First Author: Maha Hussain
Poster
2012 Genitourinary Cancers Symposium
Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.
First Author: Elizabeth J. Hovey